Introduction: Genomic alterations affecting splice sites of MNNG HOS transforming gene (MET) exon 14 were recently identified in NSCLC patients. Objective responses to MET tyrosine kinase inhibitors have been reported in these patients. Thus, detection of MET exon 14 splice site mutations represents a major challenge. So far, most of these alterations were found by full-exome sequencing or large capture-based next-generation sequencing (NGS) panels, which are not suitable for routine diagnosis.
Introduction
Targeted therapies have recently changed the care of patients with cancers displaying well-defined oncogeneaddiction-causing alterations. Several such genomic alterations have been evidenced, including mutations, translocations, and gene amplifications. In NSCLC, mutations occurring in the kinase domain of EGFR or BRAF and rearrangements involving the tyrosine kinase receptor ALK receptor tyrosine kinase (ALK) or ROS1 define unique subsets of patients who benefit from tyrosine kinase inhibitors (TKIs). Point mutations, insertions, and deletions are usually investigated by nextgeneration sequencing (NGS), with the help of commercial panels covering the main oncogenes amenable to targeted therapies. However, the spectrum of targetable molecular alterations is constantly expanding with the regular discovery of novel driver alterations in oncogenes and tumor suppressor genes. Recent publications describe a set of novel mutations located within splice sites of MNNG HOS transforming gene (MET) exon 14, causing constitutive activation of the MET receptor.
MET is a receptor tyrosine kinase produced predominantly in cells of epithelial origin. It is activated by its stromal ligand, the hepatocyte growth factor, also called scatter factor. 1 Hepatocyte growth factor and MET are essential to embryonic development and tissue regeneration in adults. [2] [3] [4] [5] [6] [7] [8] [9] Amplification of the MET gene, leading to its massive expression and ligandindependent activation, has been reported in 1% to 5% of gastric and lung cancers. [10] [11] [12] MET kinase domain mutations have also been described in various cancer types, including renal and lung cancers. 13 In a recent study, mutations at MET exon 14 splice sites were found in approximately 3% of the profiled lung tumors. 14 To date, more than 130 different mutations altering splice sites of MET exon 14 have been described. These mutations include point mutations, deletions, insertions, and complex mutations (indels), all of which affect conserved sequences of splice donor or acceptor sites. At the 5' end of the exon, most of the alterations are deletions, insertions, and indels affecting the splice acceptor site, the branch point, or the polypyrimidine tract. At the 3' end, most are point mutations affecting the splice donor site. 15 All these alterations are thought to induce in-frame exon 14 skipping, which leads to deletion of the juxtamembrane domain of the MET receptor. This juxtamembrane domain is a well-known negative regulatory domain containing at least three regulatory sites: (1) a ligand-dependent phosphorylated tyrosine residue (Y1003) involved in receptor degradation through recruitment of the ubiquitin ligase CBL proto-oncogene (CBL), (2) a phosphorylated serine residue (S985) involved in downregulation of MET kinase activity, and (3) a caspase cleavage site involved in MET degradation during apoptosis. Thus, MET exon 14 splicing and subsequent juxtamembrane domain skipping result in constitutive MET activation (for a review see Cortot et al. 16 ).
Importantly, several case reports describe objective responses to MET-targeting TKIs in patients with such mutations, and preliminary results of a phase I clinical trial reported a 39% objective response rate with crizotinib. 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Thus, identifying NSCLC patients harboring MET exon 14 splice site mutations has become an important goal. Given the expected low rate of such mutations, clinicians need a sensitive routine method for detecting them to identify all patients liable to benefit from MET TKI treatment.
MET exon 14 splice site mutations have been found mainly by whole-exome sequencing, large-hybridcapture-based NGS, or Sanger sequencing of MET.
14,15,28-30 Such technologies are not applicable in routine practice because of high cost, the need to use large tumor samples, or a lack of sensitivity. In contrast, targeted NGS, now widely implemented in molecular laboratories, allows comprehensive routine molecular profiling of tumor samples enabling the detection of known altered oncogenes and tumor suppressors. Commercially available panels, however, are not suitable for detecting the wide range of MET exon 14 splice site mutations because of the great diversity and specific localization of these alterations. 31 Here we describe a method for detecting MET exon 14 splice site mutations. It can be implemented in routine practice and is based on combining fragmentlength analysis with optimized targeted NGS.
Materials and Methods
Tumor Samples and DNA/RNA Extraction Formalin-fixed paraffin-embedded (FFPE) samples from non-small cell lung tumors were received in our laboratory between October 2015 and December 2017, in the context of daily practice. Before molecular analysis, a hematoxylin-and-eosin-stained slide was prepared from each tumor and examined by a pathologist. The pathologist evaluated the tumor cell content. If easily feasible, macrodissection was performed to enhance the tumor cell content. DNA was extracted from FFPE tumor blocks. Briefly, 10-mm-thick sections were cut from each block. After removing the paraffin with Deparaffinization Solution (Qiagen, Courtaboeuf, France), DNA was extracted with the QIAamp FFPE tissue kit (Qiagen) according to the manufacturer's instructions. Extracted DNA was quantified with the Quant-it PicoGreent dsDNA Assay Kit (Thermofisher Scientific, Courtaboeuf, France) on a Xenius XC spectrofluorometer (Safas, Monaco). Immunohistochemistry (IHC) (for MET expression) and fluorescence in situ hybridization (FISH) (for detection of MET gene amplification) were performed on 4-mm-thick FFPE sections. RNA was extracted from three 20-mm-thick sections of each available FFPE tumor block. This was done with the Total RNA FFPE tissue kit (Macherey-Nagel, Inc., Bethlehem, Pennsylvania) according to the manufacturer's instructions.
NGS Panel Design
The panel designed for FFPE samples was developed with the AmpliSeq designer software (Thermofisher Scientific) with white glove assistance to cover some positions. These targets were partially selected from the Ion AmpliSeq Colon and Lung Research Panel V2, and the panel was optimized to cover the whole MET exon 14 to detect most of the described variants. Additional targets included partial or entire exons of the following selected genes: ACVR1, AKT1, ALK, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, H3F3A, H3F3B, HIST1H3B, HIST1H3C, HRAS, IDH1, IDH2, KRAS, KIT, MAP2K1, MET, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, SMAD4, and TP53. The designed panel named CLAPv1 is provided in Supplementary Table S3 .
Library Preparation
AmpliSeq libraries were prepared with the Ion AmpliSeq Library Kit 2.0, the Ion Xpress Barcode Adapter Kit, and primers (Ion AmpliSeq custom panel or Colon and Lung V2) (Thermofisher Scientific). Ten nanograms of each DNA sample were used as template to prepare the library according to the manufacturer's instructions. Quality control and quantification of all libraries were performed on the Agilent 2200 (Agilent Technologies, Inc., Wilmington, Delaware) Tapestation using the High Sensitivity D1000 ScreenTape assay. After normalization, the libraries were pooled. Emulsion polymerase chain reaction (PCR) was used to clonally amplify the obtained library pool, diluted to 65 mmol/L. Emulsion PCR, enrichment, and chip loading were performed on an Ion Chef instrument with the Ion P Hi-Chef Kit or the Ion 54 Kit-Chef (Thermofisher Scientific). Samples were sequenced using Ion P1 chips on the Ion Proton System or Ion 540 chips on the Ion S5XL system (Thermofisher Scientific). Forty-eight barcoded samples were loaded per chip, that is, 45 patient tumor samples and 3 control samples. A positive control, a negative control, and a nontemplate control were analyzed on each run to ensure the analytical performance of the assay. Data were analyzed with Torrent Suite Software v.5.2.2 (Thermofisher Scientific). Variant calling was performed with optimized settings (available on demand). The variants obtained were annotated with the Variant Effect Predictor. 32 Control sample analysis and quality metrics were checked on each sample to avoid false results: mean read length greater than 108 bp and number of variants less than 35 . If these quality metrics were not achieved, the sample was considered not interpretable. The lower limit of detection for our NGS assays was approximately 5% mutated DNA (i.e., 10% tumor cells). If a sample contained less than 10% tumor cells and no mutation on any driver gene, it was considered not interpretable (risk of false-negative results). For a wild-type (WT) call, a minimum of 500Â was required.
IHC
For MET IHC staining, the Ultra automated slide processing system (Ventana Roche, Tucson, Arizona) was used according to the manufacturer's protocol, with rabbit monoclonal primary antibody against MET (CONFIRM Anti-Total MET, clone SP44, Ventana), as previously described. 33 
FISH
Gene copy number (GCN) and MET gene amplification were determined by FISH as previously described. Evaluation of MET GCN was performed on the whole slide for each sample. Signals were counted in at least 100 nonoverlapping nuclei per slide, with an epifluorescence microscope (Olympus BX63) and an automated imaging application (BioView, Abbott, Berkshire, United Kingdom). The following data were recorded for each sample: mean MET GCN per cell and the MET/CEN7 ratio.
Tumors were classified according to the MET amplification status, which provides the clearest definition of a MET-GCN-gain-addicted state. This status was defined as follows: high-level amplification, when the MET/CEN7 ratio was greater than or equal to 5 or when 10% or more of the tumor cells displayed clusters or 15 or more copies of the MET gene; intermediate-level amplification when the MET/CEN7 ratio was greater than 2.2 but less than 5; low-level amplification when the MET/CEN7 ratio was 1.8 or more but less than or equal to 2.2. All other tumors were classified as negative. 35 
Fragment-Length Analysis
Intron sequences flanking exon 14 of MET were amplified with two primer pairs in one tube. The primer pair for MET1 was: MET1_F 5'-CATGAGTTCTGGG CACTGG, MET1_R 5'6-FAM-CTTCTGGAAAAGTAGCTCGG and the primer pair for MET 2 was: MET2_F 5'TAAGTGCCCGAAGT GTAAGC, MET2_R 5'HEX-CAA CAATGTCACAACCCACTG. PCR was performed in a 25-mL
primer pair, and 5 to 25 ng DNA. The cycling conditions were: 95 C for 15 minutes, followed by 33 cycles of 95 C for 30 seconds, 62 C for 30 seconds, 72 C for 30 seconds, and a final extension of 72 C for 10 minutes. Fluorescent amplified products were separated on an ABI Prism 3130XL analyzer (Thermofisher Scientific). Data were interpreted with GeneMapper software version 4.1 (Thermofisher Scientific) followed by visual inspection. The lower limit of detection of the fragment analysis assay was approximately 10% mutated DNA (i.e., 20% tumor cells).
Real-Time Reverse Transcribed-PCR and Melting Curves
Total cDNA was reverse-transcribed from total RNA with random hexamers, using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, Foster City, California). Two primer pairs in exons flanking exon 14 of MET were designed to generate fragments of different sizes and melting temperatures for wild type MET and MET displaying exon 14 skipping. The primer pair A was: MET3: 5'-GGTTTTTCCTGTGGCTGAAA, MET4: 5'-GGCATGAACCGTTCTGAGAT and the primer pair B was: MET5: 5'CCAGATCAGAATTTCACAGG and MET4. Fragments were amplified with Fast SYBR Green mix (Applied Biosystems) in an Mx3005P instrument (Agilent), as described by the supplier. The cycling conditions were: 95 C for 5 minutes, followed by 40 cycles of 95 C for 15 seconds, 60 C for 30 seconds, and a final cycle 95 C for 1 minute, 55 C for 30 seconds and 95 C for 30 seconds. The dissociation curves of the amplified products were analyzed with MxPro software version 4.10. The PCR products were separated on 2.0% agarose gels and visualized under ultraviolet light.
Copy Number Analysis of the NGS Data
The count assigned to each amplicon for each sample was computed from bam files with bedtools coverage [bedtools], taking into account only reads showing a 95% overlap with the amplicon. 36 Log read counts were normalized on the basis of the GC percentage and size of each amplicon, the Guanine Cytosine (GC) percentages of the forward and reverse primers, and also the GC percentage of a 150-kb window around the amplicon as in [WACA] . 37 We also normalized the read count with respect to the derivative log ratio spread (DLRS) introduced by Agilent Technologies for comparative genomic hybridization arrays to take DNA quality into account. All normalizations were performed with a multiple linear model in one step. The log2 ratio of each amplicon for each sample was computed as the log2 of the number obtained by dividing the normalized read count for a particular sample by the median read count of all samples. Segmentation of the log2 ratio was performed with the CNA package of R, implementing the circular binary segmentation method. 38 We only kept segments with a mean log2 ratio above max (1.5 Â DLRS, 1) or below min (-1.5 Â DLRS, -0.5) and encompassing at least 3 amplicons.
Results

Optimization of Targeted NGS and Fragment Analysis for Detecting MET Exon 14 Splice Site Mutations
Between November 2015 and August 2017, 1826 FFPE tumor samples from 1722 NSCLC patients were received in our laboratory for molecular screening as part of its routine practice. All samples were tested with the "Colon&Lung V2" NGS panel. For 208 of the 1722 patients (12%), the sequencing data were not interpretable because of poor DNA quality or insufficient quantity (138 patients) or a low number of tumor cells (70 patients). Among the 1514 remaining patients, the main mutations detected were KRAS (36.2%), EGFR (13.1%), BRAF (4%), and ERBB2 (0.3%) mutations (Fig. 1A) . MET exon 14 splice site mutations were detected in 4 patients (0.3%) (Fig. 1A, Supplementary Table 1A) .
To optimize detection of the wide range of MET exon 14 splice site mutations, we developed two alternative molecular screens, one based on fragment-length analysis and one on optimized targeted NGS. We set up a fragmentlength analysis with primers surrounding either the 5' (225 bp) or the 3' end (142 bp) of exon 14, covering 91% of the previously identified deletions (Fig. 2) . 15 Among the 1514 samples screened by fragment-length analysis and yielding interpretable results, 16 MET exon 14 splice site mutations (1.1%) were detected, including mutations in both the 5' and 3' ends of exon 14 (Fig. 3A , Supplemental Table 1A ). Differences between mutant and WT alleles ranged from 1 to 55 bp. Representative fragment analyses of WT and mutant samples are shown ( Supplemental  Figs. 1A, B, and C) . One complex indel (patient 21) detected with the Colon&Lung V2 panel (mutant allele frequency: 3%) (Supplemental Table 1A ) was not picked up by the fragment analysis.
An optimized NGS panel named CLAPv1 (Colon&Lung Adapted Panel Version 1) was derived from the Colon&-Lung V2 panel. It contained 182 amplicons ranging from 62 to 154 bases in size (mean, 112 bases) and spanning 12.93 kb of the human genome (hg19) in 2 pools. This CLAPv1 panel was notably designed to better cover MET exon 14 splice site mutations, using 3 amplicons respectively covering the 140 bp of exon 14, 97 bp of intron 13, and 36 bp of intron 14. These amplicons thus cover 87% of the MET exon 14 alterations previously described (Fig. 2) . 15 The CLAPv1 panel was also designed to allow detection of all main molecular targets previously covered by the Colon&Lung V2 panel, including key genes involved in NSCLC and colorectal cancer, melanoma, stromal gastrointestinal tumors, and glioma.
To assess the efficacy of using the CLAPv1 panel to detect MET exon 14 alterations while maintaining accurate detection of all the other targeted genomic regions, we selected 52 samples already known to harbor various mutations, including 20 samples harboring MET exon 14 splice site mutations. These 52 samples were sequenced again with CLAPv1. Coverage depth analysis of the first sequencing run showed efficient sequencing with an average of 8510Â (Supplemental Fig. 2 ). Only 3 amplicons among the 182 amplicons had a median coverage depth below 500Â, corresponding to ERBB2 exon 19: AA 761 to 769 (NM_004448.3) and FGFR3 exons 6 and 9: AA 229 to 247 and 369 to 375 (NM_000142.4) (Supplemental Fig. 2) . Eighteen of the 20 MET exon 14 splice site mutations were detected with the CLAPv1 panel. The two remaining mutations were two large deletions (50 and 55 bp, patients 14 and 15) preventing primer hybridization (Supplemental Table 1A ). Importantly, these two deletions were detected by fragment-length analysis, suggesting that the two techniques are complementary. Furthermore, all known mutations in other genes were confirmed with the CLAPv1 panel (data not shown). For example, 10 EGFR mutations with allelic fractions between 3.5% and 88% were picked up.
Routine Detection of MET Exon 14 Mutations in NSCLC Cancer Patients
On the basis of these results, both the CLAPv1 panel and fragment-length analysis were further implemented in routine practice for molecular testing of NSCLC patients. Among 402 samples analyzed over 5 months, 365 samples (91%) had interpretable sequencing results, among which 8 tumors (2.2%) displayed MET exon 14 splice site mutations. All were found with the CLAPv1 panel and 4 of them were also detected by fragmentlength analysis (Fig. 3B and Supplemental Tables 1A and B). Other oncogenic drivers detected in this series of patients included 47 EGFR mutations (12.9%), 133 KRAS mutations (36.4%), 18 BRAF mutations (4.9%), and 3 ERBB2 mutations (0.8%) (Fig. 1B) .
Altogether, MET exon 14 splice site mutations were found in 30 patients (Fig. 4) . The CLAPv1 panel assay detected 26 mutations among the 28 samples tested (93%), and combining fragment-length analysis with the CLAPv1 panel assay allowed detection of 100% of the mutations (Fig. 4) . The main clinical characteristics of the 30 MET-mutated NSCLC patients are presented in Table 1 (see also Supplemental Table 2 for individual patient data).
Validation of MET Exon 14 Skipping
To assess MET exon 14 skipping in the patients displaying splice site mutations, mRNA was extracted from seven tumor samples of six patients and analyzed by SYBR green fluorescence real-time PCR. We designed two sets of specific primers both able to discriminate splicing isoforms on the basis of the melting curves of the PCR products. PCR with the primers set A from a control WT MET FFPE sample or from EBC1 cell line having a WT MET isoform, amplified a 216 bp product and the melting curve analysis revealed a single peak at 77. 4 C. The amplicon size of PCR from Hs746T and H596 cells, showing MET exon 14 skipping was 58 bp and the melting curves displayed a separate peak at approximately 72 C (Supplemental Figs. 3A and C). PCR with the primers set B generated a 286 bp amplicon, from the control WT MET FFPE sample or cell line, with a dissociation temperature of 77.3 C and a 128 bp amplicon from the MET exon 14 skipping cell lines with a dissociation temperature of 74.8 C (Supplemental Figs. 3B and D) . For six patients, paraffin-embedded tumor material was available (for patient 7, two samples were available and thus analyzed) and messenger RNAs were extracted, retrotranscribed and analyzed by PCR. For five patients of six, analysis showed exon 14 skipping with both primers sets. For patient 14, the exon 14 skipping was revealed with the primers set A, whereas primer set B did not allow PCR product detection. These results show that the identified genomic mutations of these six patients lead to MET exon 14 skipping. Furthermore, the mutations of eight patients have been previously reported to induce exon 14 skipping on RNA (Supplemental Table 1 ) and the remaining 17 mutations were predicted to induce exon 14 skipping based on in silico tools. 14, 19, 21, 23, 39 Thus, all identified mutations are anticipated to induce MET exon 14 skipping.
MET Expression Level and MET GCN in Tumors Harboring Exon 14 Splice Site Mutations
To evaluate MET expression in patients harboring MET exon 14 splice site mutations, IHC staining of MET was performed on the available paraffin-embedded tumor slides. Of 30 samples, 25 were available for IHC analysis. The samples were divided into 4 grades, from no to high expression. Two patients did not express MET (IHC 0) and 7 patients showed low-level expression (IHC 1þ). MET overexpression (IHC 2þ and 3þ) was found in 16 of 25 patients (64%) (Fig. 4 and Supplemental Tables 1A and B) . Next, we performed FISH analysis on the 25 available paraffin-embedded tumor slides. Three patients displayed MET gene amplification (MET/CEN7 ratio >1.8 or the presence of clusters) and one displayed an increased MET gene copy number (>5 copies) but no significant MET/CEN7 ratio increase. All four patients displayed MET overexpression (IHC 2þ or 3þ) (Fig. 4 and Supplemental Tables 1A and B) .
In parallel, CLAPv1 sequencing data were analyzed to measure potential MET GCN increases on the basis of read counts. Read count analysis was performed on 23 of the 25 samples for which FISH results were available. It revealed two samples (patients 20 and 22) with a significant MET copy number increase (Fig. 4 and Supplemental Tables 1A and B increase. In this sample, however, the read count displayed a high background, preventing accurate data interpretation (data not shown). Tumor samples from five patients with no tissue available for FISH analysis were subjected to read count analysis, and two were found to harbor an increased MET copy number (patients 10 and 16). Accordingly, these two tumor samples displayed high MET expression (IHC 3þ). Raw data are shown for samples 10, 16, 20, and 22, which displayed an increased copy number, and for sample 1, which did not (Supplemental Fig. 4 ). Taken together, the FISH and NGS data analyses revealed six MET gene amplifications or copy number increases among 30 patients (20%).
Discussion
MET exon 14 splice site mutations are different from most receptor tyrosine kinase mutations amenable to targeted therapies. Firstly, they occur either within the introns flanking exon 14 or at the junction between intron and exon 14. Secondly, MET exon 14 splice site mutations are molecularly diverse, including small and large deletions, point mutations, and indels. Consequently, detection of MET exon 14 splice site mutations requires a specific approach. Here we show that combining fragment-length analysis with adapted targeted NGS allows detection of MET exon 14 splice site mutations in 2.2% of patients in routine practice, as compared to the 0.3% detection rate obtained with nonoptimized targeted NGS alone.
MET exon 14 mutations were first reported on large retrospective cohorts. Various methods were used to detect them, including mRNA and whole-exome sequencing, large-scale targeted NGS based on hybrid capture (including 4557 exons of 287 genes), and Sanger sequencing of MET regions known to harbor such alterations. 14, 15, [28] [29] [30] These approaches are not suitable for molecular testing in routine practice, as they are expensive, time consuming, or require both large quantities of genomic DNA and in-depth bioinformatic analysis. Targeted NGS panels used in routine practice usually cover hotspots known to harbor genomic alterations. These panels, however, have not been specifically designed to cover intronic mutations such as MET exon 14 splice site mutations. It has recently been reported that none of the eight amplicon-based NGS panels commercially available is able to detect more than 63% of MET exon 14 mutations. 31 For instance, the ability of the Colon&LungV2 panel to detect MET exon 14 splice site mutations has been estimated in silico at 24%. Accordingly, we found this panel to detect only 4 MET exon 14 splice site mutations among 1514 NSCLC patients. This is only 0.3%, far below the expected rate. In contrast, the optimized CLAPv1 panel detected MET exon 14 mutations (half point mutations and half deletions) in 2.2% of NSCLC patients. In addition, the CLAPv1 panel accurately covered most of the other targeted genes, yielding rates of EGFR, KRAS, BRAF, or ERBB2 mutations similar to those reported so far. 40 As the CLAPv1 panel allows accurate identification of MET exon 14 mutated patients liable to benefit from MET TKI treatment, we provide the details of this panel in Supplementary Table 3 .
Although amplicon-based NGS assays such as the CLAPv1 panel are suitable for routine molecular screening, some well-known intrinsic limitations remain. 41 For instance, the usual bioinformatic workflows might fail to detect some deletions or insertions, or primers might fail to hybridize to the regions affected by such modifications. As approximately half of all MET exon 14 mutations are deletions or insertions, we have avoided this drawback by developing another molecular assay based on fragment length analysis. We show that two large deletions undetected by the CLAPv1 panel for lack of primer hybridization to the deleted sequence were successfully detected by fragment length analysis. Yet fragment length analysis also has potential drawbacks. First, its sensitivity is lower than that of ampliconbased NGS, as shown by the case of patient 21, whose deletion was detected with the CLAPv1 panel but not by fragment-length analysis. Second, fragment-length analysis does not provide the sequence of the mutant allele and has to be combined with sequencing of the amplified fragment. Another approach to detecting MET exon 14 alterations is mRNA analysis. We show here that melting curve analysis of fluorescent reverse transcriptase Values are presented as n (%) unless otherwise specified. ADC, adenocarcinoma; NSCLC NOS, not otherwise specified; PSC, pulmonary sarcomatoid carcinoma.
(RT)-PCR products allows effective discrimination of mRNAs with and without MET exon 14 skipping. This method is sensitive, specific, and can be applied to FFPE samples where the RNA quality is not optimal, thanks to the small size of the amplicons. This method could thus be useful, for instance, in further characterizing MET genomic mutations not initially identified as splice site mutations. Indeed, it is accepted that mutations affecting splice sites lead to exon 14 skipping, but it could be difficult to predict effect of mutations located deeper in intron 13 or within exon 14. Exon 14 mutations are highly diverse and their effect on RNA is published only for a few of them. 19, 21, 23 Overall, we identified 30 NSCLC patients harboring MET exon 14 splice site mutations. In line with previous reports, this group of patients was characterized by an advanced age (median age, 73 years), a high proportion of women (57%), and a high proportion of never-smokers (47%).
MET exon 14 skipping leads to in-frame deletion of the juxtamembrane domain. This regulatory domain contains the phosphorylated tyrosine residue 1003 involved in recruiting the E3 ubiquitin ligase CBL. 42 Mutation of this residue prevents degradation of the receptor and causes its aberrant activation. 43 Juxtamembrane deletion has been proposed to cause similar effects. 19 Patients with MET exon 14 mutations might thus display increased MET expression. Here we found 64% of the patients displaying MET exon 14 splice site mutations to show high expression of MET (IHC 2þ and 3þ), as compared to approximately 50% of unselected NSCLC patients. 33 Two patients, however, had tumors with MET exon 14 splice site mutations but no MET expression. Whether such patients can still benefit from MET TKI treatment must be investigated.
MET gene amplification is a rare event in NSCLC. It can be viewed as an oncogenic driver and has been associated with MET TKI efficacy. 44 In NSCLC patients harboring MET exon 14 splice site mutations, MET gene amplification appears more frequent (15% to 20% of tumor samples) than in other patients, but its impact on patient clinicopathologic characteristics and disease outcomes remains unclear. 29 FISH analysis of 25 tumor samples of our cohort showed the presence of increased GCN (due to gene amplification, chromosome 7 polysomy, or both) in several patients. In parallel, we set up a bioinformatic analysis to evaluate GCN on the basis of the CLAPv1 NGS data. This analysis confirmed the MET GCN increases observed by FISH and allowed, when FISH was not possible, identifying additional patients potentially harboring such alterations. Because NGS data analysis does not unambiguously identify gene amplification (which relies on observation of gene clustering or on calculating the ratio of the number of gene copies to the number of chromosome centromeres) this method remains indicative and cannot substitute for FISH analysis. Constitution of a larger cohort of MET exon 14 splice site mutations might be needed to assess whether FISH and bioinformatic analysis of NGS data are in total agreement. Taken together, both our FISH analysis and our NGS data analysis revealed probable MET gene amplification and MET GCN increases in approximately 20% of tested patients, all of whom displayed MET overexpression as determined by IHC. Analysis of MET mutations and MET amplification raises the question of the mutant allele specific imbalance phenomenon which could have an impact on prognosis or response to treatment. 45, 46 Based on analysis of mutant allele frequency, we observed mutant allele specific imbalance in four samples from our series. Further characterization of this phenomenon in MET-mutated samples is warranted.
In conclusion, optimized targeted NGS and fragment analysis allow better routine identification of NSCLC patients harboring MET exon 14 splice site mutations. This shows that these technologies can be rapidly adapted to the routine diagnosis of recently discovered molecular alterations.
